PharmaCyte Biotech, Inc. (PMCB)

NASDAQ: PMCB · IEX Real-Time Price · USD

1.960

-0.010 (-0.51%)

At close: Jul 19, 2024, 4:30 PM

1.990

+0.030 (1.53%)

Pre-market: Jul 20, 2024, 9:29 AM EDT

PharmaCyte Biotech Income Statement

Financials in millions USD. Fiscal year is May - April.

Millions USD. Fiscal year is May - Apr.

Year Ending	TTM	Apr 30, 2023	Apr 30, 2022	Apr 30, 2021	Apr 30, 2020	Apr 30, 2019	2018 - 2008
Selling, General & Admin	5.86	5.99	3.7	2.71	3.53	3.64	Upgrade
Research & Development	0.4	0.47	0.69	0.92	0.3	0.46	Upgrade
Other Operating Expenses	-0.15	0	0	0	0	0	Upgrade
Operating Expenses	6.11	6.46	4.39	3.62	3.83	4.1	Upgrade
Operating Income	-6.11	-6.46	-4.39	-3.62	-3.83	-4.1	Upgrade
Interest Expense / Income	0	0	0	0	0	0	Upgrade
Other Expense / Income	-4.97	-2.14	-0.15	-0.07	0	-0.03	Upgrade
Pretax Income	-1.14	-4.32	-4.24	-3.55	-3.83	-4.07	Upgrade
Net Income	-1.14	-4.32	-4.24	-3.55	-3.83	-4.07	Upgrade
Preferred Dividends	10.37	0	0	0	0	0	Upgrade
Shares Outstanding (Basic)	9	19	16	1	1	1	Upgrade
Shares Outstanding (Diluted)	9	19	16	1	1	1	Upgrade
Shares Change	-54.69%	25.56%	971.73%	60.24%	23.24%	13.57%	Upgrade
EPS (Basic)	-1.20	-0.22	-0.27	-2.45	-4.23	-	Upgrade
EPS (Diluted)	-1.20	-0.22	-0.27	-2.45	-4.23	-	Upgrade
Free Cash Flow	-2.11	-3.79	-4.12	-3.33	-2.34	-2.88	Upgrade
Free Cash Flow Per Share	-0.24	-0.20	-0.27	-2.30	-2.59	-3.92	Upgrade
EBITDA	-1.14	-4.32	-4.24	-3.55	-3.83	-4.07	Upgrade
EBIT	-1.14	-4.32	-4.24	-3.55	-3.83	-4.07	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).